UNLABELLED: Abstract Conclusions: In survival analysis, the combined Charlson comorbidity index (CCI) can be considered as a prognostic factor independent of the tumor node metastasis (TNM) classification, tumor stage, and tumor location. Severe comorbidity was the factor that had the greatest impact on prognosis in cases of initial tumor. OBJECTIVE: To study the influence of comorbidity on the survival of patients undergoing surgery for larynx cancer. METHODS: This was a retrospective study of the survival of 231 patients with laryngeal cancer who underwent surgery between 1995 and 2002. The CCI was used to assess comorbidity, the Kaplan-Meier method was used for survival analysis, and the Cox proportional risk regression model was used to identify independent prognostic factors. RESULTS: The multivariate analysis of specific mortality showed that patients classified as having severe comorbidity (CCI) were more likely to die (adjusted hazard ratio (adjHR) 1.85, 95% confidence interval (CI) 1.07-3.17). This difference was more important in patients with early tumor stages than in those with advanced stages.
UNLABELLED: Abstract Conclusions: In survival analysis, the combined Charlson comorbidity index (CCI) can be considered as a prognostic factor independent of the tumor node metastasis (TNM) classification, tumor stage, and tumor location. Severe comorbidity was the factor that had the greatest impact on prognosis in cases of initial tumor. OBJECTIVE: To study the influence of comorbidity on the survival of patients undergoing surgery for larynx cancer. METHODS: This was a retrospective study of the survival of 231 patients with laryngeal cancer who underwent surgery between 1995 and 2002. The CCI was used to assess comorbidity, the Kaplan-Meier method was used for survival analysis, and the Cox proportional risk regression model was used to identify independent prognostic factors. RESULTS: The multivariate analysis of specific mortality showed that patients classified as having severe comorbidity (CCI) were more likely to die (adjusted hazard ratio (adjHR) 1.85, 95% confidence interval (CI) 1.07-3.17). This difference was more important in patients with early tumor stages than in those with advanced stages.
Authors: Collin F Mulcahy; Abdallah S R Mohamed; Aasheesh Kanwar; Katherine A Hutcheson; Alokananda Ghosh; David Vock; Randal S Weber; Stephen Y Lai; Gary Brandon Gunn; Mark Zafereo; William H Morrison; Renata Ferrarotto; Adam S Garden; David I Rosenthal; Clifton D Fuller Journal: Head Neck Date: 2018-05-13 Impact factor: 3.147
Authors: I Zapata; M Alvarez; R Hidalgo; B Pajares; M J Garcia-Anaya; M D Toledo; J M Trigo; Y Lupiañez-Perez; J A Medina; J Jaime Gomez-Millan Journal: BMC Cancer Date: 2019-12-21 Impact factor: 4.430